Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Glucose-lowering drugs may reduce risk of developing epilepsy

10

Dec 2025

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

New AAN guideline offers treatment strategies for functional seizures

10

Dec 2025

New AAN guideline offers treatment strategies for functional seizures

To help neurologists, mental health clinicians and other clinicians determine the best ways to help people manage functional seizures, the American Academy of Neurology has issued a new guideline, published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

Screen time and ADHD: why social media stands out from gaming and TV

10

Dec 2025

Screen time and ADHD: why social media stands out from gaming and TV

Over four years in a large US cohort, greater social media use was associated with small but consistent increases in inattention symptoms in children, while video games and television were not. Genetic risk for ADHD did not modify this inattention association, and analyses supported a directional link from social media use to later attention difficulties.

AI turns routine pathology slides into powerful maps of the tumor immune landscape

10

Dec 2025

AI turns routine pathology slides into powerful maps of the tumor immune landscape

A large study shows that routine H&E pathology slides contain rich spatial proteomic signals that can be decoded by AI to model the tumor immune microenvironment at population scale. By generating virtual multiplex immunofluorescence images, GigaTIME enables pan-cancer discovery of immune patterns linked to invasion stage, survival, and genomic alterations.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.